Carter RF. Do you believe that N-of-1 trials (a clinical trial in which a single patient is the entire trial), are appropriate to evaluate the effectiveness of genomic therapies for rare and/or common genetic disorders? Do gene-editing/targeting therapies have the potential to expedite the advancement of personalized medicine?. HSI [Internet]. 2017 Jun. 1 [cited 2025 Apr. 29];8(1):Page 60-Page 61. Available from: https://healthscienceinquiry.com/index.php/hsi/article/view/223